H.C. Wainwright analyst Joseph Pantginis raised the firm’s price target on Astria Therapeutics to $20 from $13 and keeps a Buy rating on the shares. The Phase 1a healthy volunteer study for STAR-0215 offered a "significant profile building data for the antibody," Pantginis tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ATXS:
- Astria Therapeutics announces pricing of $100M common stock offering
- Astria Therapeutics reports positive Phase 1a results of STAR-0215 in HAE
- Astria Therapeutics reports Q3 EPS (87c), consensus (92c)
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue